Next Article in Journal
AI-Powered Diagnosis of Skin Cancer: A Contemporary Review, Open Challenges and Future Research Directions
Previous Article in Journal
Robot-Assisted Magnetic Resonance Imaging-Targeted versus Systematic Prostate Biopsy; Systematic Review and Meta-Analysis
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Davidi et al. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo. Cancers 2022, 14, 2959

1
Novocure Ltd., Haifa 3190500, Israel
2
Novocure GmbH, 81925 Munich, Germany
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Cancers 2023, 15(4), 1182; https://doi.org/10.3390/cancers15041182
Submission received: 7 December 2022 / Accepted: 20 December 2022 / Published: 13 February 2023
The authors wish to make minor corrections to Figure 1 and Figure 2 of the following paper [1], as detailed below:
On page 6, the Y axis of Figure 1c was not correct. The corrected Figure 1 appears below.
Figure 1. Efficacy of TTFields for treatment of HCC cells. HepG2 and Huh-7D12 cells were treated with TTFields (1.0 and 1.7 V/cm RMS, respectively) for 72 h. Cell counts were determined following treatment with TTFields at a frequency range of 100–400 kHz (a). Values are mean (N ≥ 3) ± SEM. ** p < 0.01, *** p < 0.001, and **** p < 0.0001 relative to control; one-way ANOVA. Clonogenicity (b), overall effect (c), and apoptosis (d) were examined for treatment of the cells with 150 kHz TTFields. Values are mean ± SEM. ** p < 0.01, *** p < 0.001, and **** p < 0.0001 relative to control; For apoptosis assay live cells: p < 0.05 for HepG2 and p = 0.14 for Huh-7D12 relative to control; Student’s t-test. ANOVA = analysis of variance; HCC = hepatocellular carcinoma; RMS = root mean square; SEM = standard error of the mean; TTFields = Tumor Treating Fields.
Figure 1. Efficacy of TTFields for treatment of HCC cells. HepG2 and Huh-7D12 cells were treated with TTFields (1.0 and 1.7 V/cm RMS, respectively) for 72 h. Cell counts were determined following treatment with TTFields at a frequency range of 100–400 kHz (a). Values are mean (N ≥ 3) ± SEM. ** p < 0.01, *** p < 0.001, and **** p < 0.0001 relative to control; one-way ANOVA. Clonogenicity (b), overall effect (c), and apoptosis (d) were examined for treatment of the cells with 150 kHz TTFields. Values are mean ± SEM. ** p < 0.01, *** p < 0.001, and **** p < 0.0001 relative to control; For apoptosis assay live cells: p < 0.05 for HepG2 and p = 0.14 for Huh-7D12 relative to control; Student’s t-test. ANOVA = analysis of variance; HCC = hepatocellular carcinoma; RMS = root mean square; SEM = standard error of the mean; TTFields = Tumor Treating Fields.
Cancers 15 01182 g001
On page 7, the color coding was missing in Figure 2. The corrected Figure 2 appears below.
Figure 2. Effects of TTFields on autophagy levels in HCC cells. HepG2 and Huh-7D12 cells were treated with 150 kHz TTFields (1.0 and 1.7 V/cm RMS, respectively) for 72 h, and median side-scatter values were measured as representing changes in cellular granularity (a). Cells treated for 48 h were examined for LC3 foci formation by fluorescent microscopy, with or without addition of CQ during the last 3 h of the experiment (b), LC3 in green staining and DAPI in blue. Experiments performed with 24 or 48 h application of TTFields with addition of CQ during the 3 final hours of the experiments were quantified for LC3 foci formation by immunofluorescence (c), and for LC3-II to LC3-I ratio by immunoblotting (d). Values are mean (N ≥ 3) ± SEM. * p < 0.05, ** p < 0.01, and *** p < 0.001, relative to control; two-way ANOVA. ANOVA = analysis of variance; CQ = chloroquine diphosphate; DAPI = 4′,6-diamidino-2-phenylindole; HCC = hepatocellular carcinoma; ns = non-significant; RMS = root mean square; SEM = standard error of the mean; TTFields = Tumor Treating Fields.
Figure 2. Effects of TTFields on autophagy levels in HCC cells. HepG2 and Huh-7D12 cells were treated with 150 kHz TTFields (1.0 and 1.7 V/cm RMS, respectively) for 72 h, and median side-scatter values were measured as representing changes in cellular granularity (a). Cells treated for 48 h were examined for LC3 foci formation by fluorescent microscopy, with or without addition of CQ during the last 3 h of the experiment (b), LC3 in green staining and DAPI in blue. Experiments performed with 24 or 48 h application of TTFields with addition of CQ during the 3 final hours of the experiments were quantified for LC3 foci formation by immunofluorescence (c), and for LC3-II to LC3-I ratio by immunoblotting (d). Values are mean (N ≥ 3) ± SEM. * p < 0.05, ** p < 0.01, and *** p < 0.001, relative to control; two-way ANOVA. ANOVA = analysis of variance; CQ = chloroquine diphosphate; DAPI = 4′,6-diamidino-2-phenylindole; HCC = hepatocellular carcinoma; ns = non-significant; RMS = root mean square; SEM = standard error of the mean; TTFields = Tumor Treating Fields.
Cancers 15 01182 g002
The corrections do not affect the main scientific results and the final conclusions of this manuscript. The authors would like to apologize for any inconvenience caused. The original article has been updated.

Reference

  1. Davidi, S.; Jacobovitch, S.; Shteingauz, A.; Martinez-Conde, A.; Braten, O.; Tempel-Brami, C.; Zeevi, E.; Frechtel-Gerzi, R.; Ene, H.; Dor-On, E.; et al. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo. Cancers 2022, 14, 2959. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Davidi, S.; Jacobovitch, S.; Shteingauz, A.; Martinez-Conde, A.; Braten, O.; Tempel-Brami, C.; Zeevi, E.; Frechtel-Gerzi, R.; Ene, H.; Dor-On, E.; et al. Correction: Davidi et al. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo. Cancers 2022, 14, 2959. Cancers 2023, 15, 1182. https://doi.org/10.3390/cancers15041182

AMA Style

Davidi S, Jacobovitch S, Shteingauz A, Martinez-Conde A, Braten O, Tempel-Brami C, Zeevi E, Frechtel-Gerzi R, Ene H, Dor-On E, et al. Correction: Davidi et al. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo. Cancers 2022, 14, 2959. Cancers. 2023; 15(4):1182. https://doi.org/10.3390/cancers15041182

Chicago/Turabian Style

Davidi, Shiri, Sara Jacobovitch, Anna Shteingauz, Antonia Martinez-Conde, Ori Braten, Catherine Tempel-Brami, Einav Zeevi, Roni Frechtel-Gerzi, Hila Ene, Eyal Dor-On, and et al. 2023. "Correction: Davidi et al. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo. Cancers 2022, 14, 2959" Cancers 15, no. 4: 1182. https://doi.org/10.3390/cancers15041182

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop